Intellia Therapeutics to Present Data at the European Society of Gene & Cell Therapy Congress
October 14 2016 - 7:00AM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome
editing company focused on the development of potentially curative
therapeutics using CRISPR/Cas9 technology, announced that members
of its scientific team will present new data at the European
Society of Gene & Cell Therapy Congress (ESGCT) in Florence,
Italy from October 18-21, 2016. Abstracts will be available online
at esgct.eu on October 17, 2016.
“The data being presented at ESGCT show Intellia’s
continued progress with its CRISPR/Cas9 platform,” said John
Leonard, M.D., chief medical officer, Intellia Therapeutics. “These
findings are important as we learn more about CRISPR/Cas9 and move
toward clinical studies in patients.”
The following posters have been scheduled for
presentation:
Number |
Poster Title |
Presenter |
Time |
#283 |
Efficient assessment of CRISPR/Cas9 off-target activity using a
background double-strand break model |
Reynald Lescarbeau, Ph.D.Computational Scientist,
Bioinformatics |
October 19, 2016 18:30 - 20:30 pm12:30 - 2:30 pm ET |
#280 |
Robust in vivo gene editing in mouse hepatocytes with systemic
lipid nanoparticle delivery of CRISPR/Cas9 components
|
David Morrissey, Ph.D. Chief Technology Officer |
October 20, 201618:30 - 20:30 pm12:30 - 2:30 pm ET |
#320 |
DNA repair events after cleavage by CRISPR/Cas9 are not random |
Walter Strapps, Ph.D.Senior Director, Biology |
October 20, 201618:30 - 20:30 pm12:30 - 2:30 pm ET |
#310 |
Translating CRISPR/Cas9 genome editing into therapeutics |
Tom Barnes, Ph.D.Chief Scientific Officer |
October 20, 201618:30 - 20:30 pm12:30 - 2:30 pm ET |
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company,
focused on the development of proprietary, potentially curative
therapeutics using the CRISPR/Cas9 system. Intellia believes the
CRISPR/Cas9 technology has the potential to transform medicine by
permanently editing disease-associated genes in the human body with
a single treatment course. Our combination of deep scientific,
technical and clinical development experience, along with our
leading intellectual property portfolio, puts us in a unique
position to unlock broad therapeutic applications of the
CRISPR/Cas9 technology and create a new class of therapeutic
products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at
intelliatx.com; Follow us on Twitter @intelliatweets.
Media Contact:
Jennifer Mound Smoter
Chief External Affairs & Communications Officer
+1 224-804-4462
jenn.smoter@intelliatx.com
Investor Contacts:
John Graziano
Trout Group
+1 646-378-2942
jgraziano@troutgroup.com
Chad Rubin
Trout Group
+1 646-378-2947
crubin@troutgroup.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Sep 2023 to Sep 2024